BCL2 and MCL1 are commonly expressed prosurvival (antiapoptotic) proteins in
hematologic cancers and play important roles in their biology either through dysregulation or …

While the understanding of the genomic aberrations that underpin chronic and acute
myeloid leukaemia (CML and AML) has allowed the development of therapies for these …

Venetoclax with azacitidine (ven/aza) has emerged as a promising treatment regimen for
acute myeloid leukemia (AML), with a high percentage of clinical remissions in newly …

Acquired resistance represents a bottleneck for effective molecular targeted therapy in lung
cancer. Metabolic adaptation is a distinct hallmark of human lung cancer that might …

Redox biology is at the core of life sciences, accompanied by the close correlation of redox
processes with biological activities. Redox homeostasis is a prerequisite for human health …

Malignant stem cells have long been considered a key therapeutic target in leukemia.
Therapeutic strategies designed to target the fundamental biology of leukemia stem cells …

Venetoclax is a new type of BH3 mimetic compound that can target the binding site in the
BCL-2 protein and induce apoptosis in cancer cells by stimulating the mitochondrial …

The BCL2 inhibitor venetoclax has recently emerged as an important component of acute
myeloid leukemia (AML) therapy. Notably, use of this agent has revealed a previously …

Our study details the stepwise evolution of gilteritinib resistance in FLT3-mutated acute
myeloid leukemia (AML). Early resistance is mediated by the bone marrow …

Aurora kinase A (AURKA) has emerged as a drug target for glioblastoma (GBM). However,
resistance to therapy remains a critical issue. By integration of transcriptome, chromatin …